Enliven Therapeutics (NASDAQ:ELVN) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Enliven Therapeutics (NASDAQ:ELVN) posted its quarterly earnings results on Tuesday. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17, Zacks reports.

Enliven Therapeutics Trading Up 9.0 %

Enliven Therapeutics stock traded up $1.97 during trading on Thursday, hitting $23.77. 195,871 shares of the company were exchanged, compared to its average volume of 266,506. The business’s 50 day moving average is $22.77 and its 200 day moving average is $20.02. Enliven Therapeutics has a 52 week low of $9.80 and a 52 week high of $27.67. The company has a market capitalization of $1.12 billion, a P/E ratio of -11.97 and a beta of 1.10.

Analysts Set New Price Targets

Several analysts have recently commented on ELVN shares. Robert W. Baird assumed coverage on Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 target price for the company. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,000 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $23.18, for a total value of $278,160.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Samuel Kintz sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $23.18, for a total value of $278,160.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Benjamin Hohl sold 4,250 shares of the business’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $22.57, for a total value of $95,922.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 123,668 shares of company stock worth $3,057,633. Corporate insiders own 29.20% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.